Neuberger Berman Group’s Novo Nordisk NVO Stock Holding History

Neuberger Berman Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.25M	Sell	88,604 -88,461	-50%	-$3.8M	﹤0.01%	1076
2026 Q1	$6.46M	Buy	177,065 +36,322	+26%	+$1.72M	﹤0.01%	929
2025 Q4	$7.16M	Sell	140,743 -25,966	-16%	-$1.33M	0.01%	890
2025 Q3	$9.25M	Sell	166,709 -12,857	-7%	-$753K	0.01%	815
2025 Q2	$12.4M	Sell	179,566 -92	-0.1%	-$6.26K	0.01%	751
2025 Q1	$12.5M	Sell	179,658 -102,425	-36%	-$8.46M	0.01%	731
2024 Q4	$24.3M	Sell	282,083 -1,396	-0.5%	-$151K	0.02%	613
2024 Q3	$33.8M	Buy	283,479 +32,564	+13%	+$4.34M	0.03%	527
2024 Q2	$35.8M	Buy	250,915 +137,921	+122%	+$18.3M	0.03%	508
2024 Q1	$14.5M	Buy	112,994 +68,857	+156%	+$8.2M	0.01%	721
2023 Q4	$4.57M	Buy	44,137 +10,676	+32%	+$1.06M	﹤0.01%	938
2023 Q3	$3.04M	Sell	33,461 -4,011	-11%	-$353K	﹤0.01%	993
2023 Q2	$3.03M	Sell	37,472 -2,904	-7%	-$237K	﹤0.01%	997
2023 Q1	$3.21M	Buy	40,376 +846	+2%	+$60K	﹤0.01%	967
2022 Q4	$2.67M	Sell	39,530 -18	-0%	-$1.05K	﹤0.01%	1007
2022 Q3	$1.97M	Sell	39,548 -350	-0.9%	-$18.8K	﹤0.01%	1084
2022 Q2	$2.22M	Buy	39,898 +5,274	+15%	+$293K	﹤0.01%	1083
2022 Q1	$1.92M	Buy	34,624 +25,404	+276%	+$1.3M	﹤0.01%	1183
2021 Q4	$353K	Buy	9,220 +1,706	+23%	+$92.4K	﹤0.01%	1659
2021 Q3	$313K	Buy	7,514 +598	+9%	+$28.9K	﹤0.01%	1592
2021 Q2	$284K	Sell	6,916 -16	-0.2%	-$620	﹤0.01%	1633
2021 Q1	$229K	Sell	6,932 -832	-11%	-$29.6K	﹤0.01%	1673
2020 Q4	$271K	Buy	7,764 +1,110	+17%	+$38.4K	﹤0.01%	1541
2020 Q3	$231K	Buy	6,654 +64	+1%	+$2.13K	﹤0.01%	1519
2020 Q2	$216K	Sell	6,590 -1,374	-17%	-$43.8K	﹤0.01%	1469
2020 Q1	$240K	Sell	7,964 -3,630	-31%	-$108K	﹤0.01%	1388
2019 Q4	$335K	Sell	11,594 -1,940	-14%	-$53.7K	﹤0.01%	1360
2019 Q3	$350K	Buy	13,534 +2,802	+26%	+$70.9K	﹤0.01%	1346
2019 Q2	$274K	Buy	+10,732	New	+$265K	﹤0.01%	1426
2018 Q1	–	Sell	-76,676	Closed	-$2.06M	–	1724
2017 Q4	$2.06M	Sell	76,676 -13,716	-15%	-$349K	﹤0.01%	1022
2017 Q3	$2.18M	Sell	90,392 -928	-1%	-$21K	﹤0.01%	978
2017 Q2	$1.96M	Buy	91,320 +2,666	+3%	+$53.8K	﹤0.01%	1006
2017 Q1	$1.52M	Buy	88,654 +16,954	+24%	+$295K	﹤0.01%	1066
2016 Q4	$1.29M	Buy	71,700 +15,146	+27%	+$275K	﹤0.01%	1081
2016 Q3	$1.18M	Buy	56,554 +18,006	+47%	+$446K	﹤0.01%	1070
2016 Q2	$1.04M	Buy	38,548 +1,728	+5%	+$47.4K	﹤0.01%	1092
2016 Q1	$998K	Sell	36,820 -43,988	-54%	-$1.18M	﹤0.01%	1103
2015 Q4	$2.35M	Sell	80,808 -3,360	-4%	-$93K	﹤0.01%	984
2015 Q3	$2.28M	Buy	84,168 +4,012	+5%	+$114K	﹤0.01%	1005
2015 Q2	$2.19M	Buy	80,156 +9,412	+13%	+$265K	﹤0.01%	1045
2015 Q1	$1.89M	Buy	70,744 +3,940	+6%	+$90.7K	﹤0.01%	1080
2014 Q4	$1.41M	Sell	66,804 -11,520	-15%	-$257K	﹤0.01%	1139
2014 Q3	$1.86M	Buy	78,324 +5,990	+8%	+$138K	﹤0.01%	1124
2014 Q2	$1.67M	Sell	72,334 -3,252	-4%	-$71.8K	﹤0.01%	1149
2014 Q1	$1.73M	Buy	75,586 +13,246	+21%	+$282K	﹤0.01%	1109
2013 Q4	$1.15M	Buy	62,340 +6,840	+12%	+$119K	﹤0.01%	1182
2013 Q3	$939K	Buy	55,500 +8,110	+17%	+$136K	﹤0.01%	1203
2013 Q2	$734K	Buy	+47,390	New	+$789K	﹤0.01%	1238

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Neuberger Berman Group's NVO Position: Q2 2026 in Review

Neuberger Berman Group reduced its Novo Nordisk (NVO) stake by 50% in Q2 2026, selling an estimated $3.8M and leaving 88,604 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1076.

Neuberger Berman Group first reported a position in NVO in Q2 2013 and has held it in 48 quarters since. The position peaked at $35.8M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Neuberger Berman Group held 88,604 shares of Novo Nordisk worth $4.25M as of Q2 2026.
Neuberger Berman Group sold 88,461 Novo Nordisk shares in Q2 2026, an estimated $3.8M.
Novo Nordisk made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1076 holding.
Neuberger Berman Group first reported a position in Novo Nordisk in Q2 2013 and has held it in 48 quarters since.
Neuberger Berman Group's Novo Nordisk position peaked at $35.8M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.